NEW YORK, Aug. 30, 2017 /PRNewswire/ -- Attorney Advertising --
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acorda Therapeutics Inc.
("Acorda" or the "Company") (NASDAQ: ACOR). Such investors are encouraged to obtain additional information and
assist the investigation by visiting the firm's site: www.bgandg.com/acor.
The investigation concerns whether Acorda and certain of its officers and/or directors have violated Sections 10(b) and
20(a) of the Securities Exchange Act of 1934.
On August 29, 2017 before market-hours, Acorda revealed that it had received a Refusal To File
("RTF") letter from the U.S. Food and Drug Administration ("FDA") regarding its New Drug Application for Inbrija, Acorda's
treatment for Parkinson's disease. Acorda notified investors that "[u]pon its preliminary review, FDA determined that the
NDA, submitted on June 26, 2017, was not sufficiently complete to permit a substantive review.
FDA specified two reasons for the RTF: first, the date when the manufacturing site would be ready for inspection, and,
second, a question regarding the submission of the drug master production record. FDA also requested additional information at
resubmission, which was not part of the basis for the RTF." Following this news, Acorda stock has dropped $6.25 per share, or 24.32%, to close at $19.45 on August
29, 2017.
If you are aware of any facts relating to this investigation, or purchased shares of Acorda, you can assist this
investigation by visiting the firm's site: www.bgandg.com/acor. You can also contact Peretz Bronstein or his Investor
Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC:
212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive
pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor
plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as
well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
View original content with multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-acorda-therapeutics-inc-acor-300511412.html
SOURCE Bronstein, Gewirtz & Grossman, LLC